News | June 28, 2023
Oncodesign Services announce access to ImaginAb’s CD8 ImmunoPET technology
Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement
Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
The production and supply in Canada are designed to address the growing need for no-carrier-added Lutetium-177 (n.c.a. Lu-177) in North America
Healthcare is timely and personal – and its delivery should be too
Expansion of leading biomarker and bioanalysis company enhances bioanalytical solutions for targeted radiopharmaceuticals
Lilly may be eligible for up to US $ 225m in payments based upon the achievement of pre-specified development, regulatory and commercial milestones
Equity investment follows recent EUR 520 m licensing agreement providing Grand Pharma (GP) access to three of ITM’s targeted radionuclide therapeutic and diagnostic candidates for Greater China
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
The company is doubling its chemistry research capacity that should commission by Q2'FY22
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
Subscribe To Our Newsletter & Stay Updated
